Dodecanedioic Acid and Its Effects on Liver Disease and Obesity
Author Information
Author(s): Giulia Angelini, Sara Russo, Fabrizia Carli, Patrizia Infelise, Simona Panunzi, Alessandro Bertuzzi, Maria Emiliana Caristo, Erminia Lembo, Roberta Calce, Stefan R. Bornstein, Amalia Gastaldelli, Geltrude Mingrone
Primary Institution: Università Cattolica del Sacro Cuore, Rome, Italy
Hypothesis
DC12 could improve liver function by inhibiting the citrate/Na+ symporter, which is highly active in hepatocytes.
Conclusion
Dodecanedioic acid (DC12) prevents and reverses metabolic-associated liver disease and obesity by targeting key metabolic pathways in the liver.
Supporting Evidence
- Rats given DC12 experienced significant reductions in weight gain and liver fat.
- DC12 improved glucose tolerance and insulin sensitivity in the rats.
- Liver histology showed protection against diet-induced metabolic-associated steatohepatitis (MASH).
- DC12 supplementation led to a significant reduction in hepatic steatosis and fibrosis.
- Plasma lipid profiles showed lower triglycerides and phosphatidylcholines in the DC12 group.
- DC12 reduced hepatic lipogenesis enzymes and increased fatty acid β-oxidation.
- Half of the DC12 ingested was taken up by the liver during the first pass.
Takeaway
Dodecanedioic acid helps rats lose weight and improves their liver health by changing how their bodies process fat and sugar.
Methodology
Rats were divided into two groups and fed a high-fat diet with or without DC12 supplementation for 8 to 14 weeks, followed by assessments of weight, liver health, and metabolic parameters.
Limitations
The study did not measure energy expenditure using respiratory chambers.
Participant Demographics
Forty adult Wistar male rats, aged 8–10 weeks.
Statistical Information
P-Value
0.009
Confidence Interval
CI: 18.48–21.22%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website